avenciguat
Small moleculeexperimental
Clinical trial activity
16 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2016 (NCT02694354)
Timeline
Indications
Mechanism of action
NPR1 activator
Chemistry & pharmacology
Loading structure…
SMILES
CCOc1c(C(=O)O)cnn1-c1cccc(-c2cccc(C)c2OCc2ccc3c(c2C)CCN(C2CCOCC2)C3)n1- Mol. weight
- 582.7 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314503 ↗
Also known as
- bi 685509
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06272058 | Phase 1 | Mar 20, 2024 | Boehringer Ingelheim |
| NCT06193811 | Phase 1 | Jan 16, 2024 | Boehringer Ingelheim |
| NCT06082843 | Phase 2 | Jan 8, 2024 | Boehringer Ingelheim |
| NCT05559580 | Phase 2 | Nov 24, 2022 | Boehringer Ingelheim |
| NCT05515328 | Phase 1 | Sep 8, 2022 | Boehringer Ingelheim |
| NCT05282121 | Phase 2 | May 26, 2022 | Boehringer Ingelheim |
| NCT05161481 | Phase 2 | Jan 14, 2022 | Boehringer Ingelheim |
| NCT04926246 | Phase 1 | Jul 1, 2021 | Boehringer Ingelheim |
| NCT04750577 | Phase 2 | Apr 27, 2021 | Boehringer Ingelheim |
| NCT04736628 | Phase 2 | Apr 27, 2021 | Boehringer Ingelheim |
| NCT03842761 | Phase 1 | Mar 6, 2019 | Boehringer Ingelheim |
| NCT03259464 | Phase 1 | Sep 4, 2017 | Boehringer Ingelheim |
| NCT03165227 | Phase 1 | Jul 13, 2017 | Boehringer Ingelheim |
| NCT03116906 | Phase 1 | Apr 24, 2017 | Boehringer Ingelheim |
| NCT03116893 | Phase 1 | Apr 19, 2017 | Boehringer Ingelheim |
| NCT02694354 | Phase 1 | Mar 1, 2016 | Boehringer Ingelheim |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boehringer Ingelheim | For profit | 16 | 16 | 2 | 2016 |
1 organizations
Page 1 / 1